Table 1 Clinicopathologic characteristics and mutation status of patients with lung adenocarcinoma stratified by PD-L1 and IDO1 expression on tumor cells

From: Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas

Variable

PD-L1+

PD-L1−

P1

IDO1+ 

IDO1−

P2

IDO1+/PD-L1−

IDO1+/PD-L1+

P3

N a

89

172

 

74

186

 

25

49

 

Mean age (SD)

68 (10)

68 (10)

0.630

67 (10)

69 (10)

0.170

64 (10)

68 (10)

0.380

Sex, n (%)

  

0.784

  

0.148

  

0.383

 F

57 (64)

114 (66)

 

43 (58)

127 (68)

 

13 (52)

30 (61)

 

 M

32 (36)

58 (34)

 

31 (42)

59 (33)

 

12 (48)

19 (39)

 

Smoking status, n (%)

         

 ≥10 PPY

81 (92)

123 (72)

<0.001

63 (86)

141 (76)

0.089

19 (76)

44 (90)

0.082

 ≥30 PPY

65 (75)

84 (49)

<0.001

51 (70)

98 (54)

0.018

14 (56)

37 (76)

0.105

Tumor size, cm (IQR)

2.1 (2)

1.9 (2)

0.092

2.0 (1)

2.0 (2)

0.169

1.5 (1)

2.0 (2)

0.070

T status (pT), n (%)

  

0.037

  

0.252

  

0.011

 T1

51 (57)

116 (67)

 

53 (72)

113 (61)

 

20 (80)

33 (67)

 

 T2

33 (37)

38 (22)

 

18 (34)

53 (29)

 

3 (12)

15 (31)

 

 T3

5 (6)

13 (8)

 

3 (4)

15 (8)

 

2 (8)

1 (2)

 

 T4

0

5 (3)

 

0

5 (3)

 

0

0

 

N status (pN)b, n (%)

  

0.039

  

0.310

  

1.000

 N0

65 (73)

147 (86)

 

59 (80)

152 (82)

 

20 (80)

39 (80)

 

 N1

11 (12)

8 (5)

 

8 (11)

11 (6)

 

2 (8)

6 (12)

 

 N2

8 (9)

7 (4)

 

5 (7)

10 (5)

 

2 (8)

3 (6)

 

Pathologic stage (AJCC), n (%)

  

0.438

  

0.917

  

1.000

 I

66 (74)

135 (79)

 

59 (80)

141 (76)

 

20 (80)

40 (82)

 

 II

11 (12)

23 (13)

 

8 (11)

26 (14)

 

2 (8)

5 (10)

 

 III

11 (12)

11 (6)

 

6 (8)

16 (9)

 

2 (8)

4 (8)

 

 IV

1 (1)

3 (2)

 

1 (1)

3 (2)

 

1 (4)

0

 

Predominant pattern (IASLC), n (%)

  

<0.001

  

<0.001

  

<0.001

 MIA

2 (2)

18 (11)

 

3 (4)

17 (9)

 

1 (4)

2 (4)

 

 Lepidic

8 (9)

23 (13)

 

7 (10)

24 (13)

 

2 (8)

5 (10)

 

 Acinar

39 (44)

65 (38)

 

40 (54)

63 (34)

 

17 (68)

23 (47)

 

 Papillary

5 (6)

34 (20)

 

3 (4)

36 (19)

 

2 (8)

1 (2)

 

 Micropapillary

1 (1)

2 (1)

 

1 (1)

2 (1)

 

1 (4)

0

 

 Solid

34 (38)

9 (5)

 

18 (24)

25 (13)

 

0

18 (37)

 

 IMA

0

18 (11)

 

1 (1)

17 (9)

 

1 (4)

0

 

 Fetal

0

3 (2)

 

1 (1)

2 (1)

 

1 (4)

0

 

Nuclear grade, n (%)

  

<0.001

  

0.007

  

<0.001

 1

0

7 (4)

 

0

7 (4)

 

0

0

 

 2

34 (38)

131 (76)

 

39 (53)

126 (68)

 

21 (84)

18 (37)

 

 3

55 (62)

34 (20)

 

35 (47)

53 (29)

 

4 (16)

31 (63)

 

Pleural invasion, n (%)

  

0.207

  

0.490

  

0.533

 0

71 (80)

149 (87)

 

60 (81)

159 (86)

 

19 (76)

41 (84)

 

 1

18 (20)

23 (13)

 

14 (19)

27 (15)

 

6 (24)

8 (16)

 

Lymphatic invasion, n (%)

  

<0.001

  

0.011

  

0.051

 0

35 (39)

122 (71)

 

35 (47)

121 (65)

 

16 (64)

19 (39)

 

 1

54 (61)

50 (29)

 

39 (53)

65 (35)

 

9 (36)

30 (61)

 

Vascular invasion, n (%)

  

<0.001

  

0.040

  

0.290

 0

57 (64)

152 (88)

 

53 (72)

155 (83)

 

20 (80)

33 (67)

 

 1

32 (36)

20 (12)

 

21 (28)

31 (17)

 

5 (20)

16 (33)

 

CD8+ tumor-infiltrating lymphocytes, n (%)

  

<0.001

  

<0.001

  

<0.001

 0–1

30 (34)

166 (97)

 

39 (53)

156 (84)

 

25 (100)

14 (29)

 

 2–3

59 (66)

6 (4)

 

35 (47)

30 (16)

 

0

35 (71)

 

CD8+ stroma, n (%)

  

<0.001

  

<0.001

  

0.001

 ≤10%

32 (36)

133 (77)

 

33 (45)

132 (71)

 

18 (72)

15 (31)

 

 >10%

57 (64)

39 (23)

 

41 (55)

54 (29)

 

7 (28)

34 (69)

 

T-bet+ tumor-infiltrating lymphocytes, n (%)

  

<0.001

  

0.010

  

0.073

 0–1

65 (73)

166 (97)

 

59 (80)

171 (92)

 

23 (92)

36 (74)

 

 2–3

24 (27)

6 (4)

 

15 (20)

15 (8)

 

2 (8)

13 (27)

 

T-bet+ stroma, n (%)

  

0.055

  

0.228

  

1.000

 ≤5%

68 (76)

149 (87)

 

58 (78)

159 (86)

 

20 (80)

38 (78)

 

 >5%

21 (24)

23 (13)

 

16 (22)

27 (15)

 

5 (20)

11 (22)

 

GATA3+ tumor-infiltrating lymphocytes, n (%)

  

1.000

  

1.000

  

1.000

 0–1

88 (99)

170 (99)

 

73 (99)

184 (99)

 

25 (100)

48 (98)

 

 2c

1 (1)

2 (1)

 

1 (1)

2 (1)

 

0

1 (2)

 

GATA3+ stroma, n (%)

  

0.105

  

0.149

  

1.000

 ≤5%

70 (79)

150 (87)

 

58 (78)

161 (87)

 

20 (80)

38 (78)

 

 >5%

19 (21)

22 (13)

 

16 (22)

25 (13)

 

5 (20)

11 (22)

 

Molecular alterations, n (%)

  

<0.001

  

0.832

  

0.018

 KRAS mutations

46 (52)

62 (36)

 

29 (39)

78 (42)

 

7 (28)

22 (45)

 

 EGFR mutations

5 (6)

49 (29)

 

13 (18)

41 (22)

 

9 (36)

4 (8)

 

 ALK rearrangements

1 (1)

3 (2)

 

1 (1)

3 (2)

 

1 (4)

0

 

 Other alterations

4 (5)

9 (5)

 

4 (5)

9 (5)

 

1 (4)

3 (6)

 

 SNaPshot wild type

33 (37)

49 (29)

 

27 (37)

55 (30)

 

7 (28)

20 (41)

 
  1. PD-L1 programmed cell death ligand 1, IDO1 indoleamine 2,3-dioxygenase 1, IQR interquartile range, PPY pack per year, AJCC American Joint Committee on Cancer, IASLC International Association for the Study of Lung Cancer, MIA minimally invasive adenocarcinoma, IMA invasive mucinous adenocarcinoma, stroma lymphocytes in the tumor stroma
  2. aOne case did not have assessable IDO1 staining
  3. bpN data were not available for N = 15 cases
  4. cNo case with a score of 3 for GATA3+ TILs was identified in this cohort
  5. Bold values are significant P values
Back to article page